YU61503A - Nova so benzoilgvanidina - Google Patents

Nova so benzoilgvanidina

Info

Publication number
YU61503A
YU61503A YU61503A YUP61503A YU61503A YU 61503 A YU61503 A YU 61503A YU 61503 A YU61503 A YU 61503A YU P61503 A YUP61503 A YU P61503A YU 61503 A YU61503 A YU 61503A
Authority
YU
Yugoslavia
Prior art keywords
salt
novel
novel benzoylguanidine
benzoylguanidine salt
pyrrolylcarbonyl
Prior art date
Application number
YU61503A
Other languages
English (en)
Inventor
Christian Eickmeier
Peter Sieger
Volkmar Korner
Rolf Ulrich Wilhelm Herter
Werner Rall
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg
Publication of YU61503A publication Critical patent/YU61503A/sh
Publication of RS52014B publication Critical patent/RS52014B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pronalazak se odnosi na hidrohlorid 4-[4-(2-pirolilkarbonil)-1-piperazinil]-3-trifluorometil-benzoilgvanidina, na postupak za njegovo pripremanje kao i na njegovu primenu za pripremanje leka.[The invention relates to 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethyl-benzoylguanidine hydrochloride, a method for the production thereof and the use of the same for producing a pharmaceutical.
YU61503A 2001-02-15 2002-02-14 Nova so benzoilgvanidina RS52014B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10106970A DE10106970A1 (de) 2001-02-15 2001-02-15 Neues Benzoylguanidinsalz
PCT/EP2002/001535 WO2002064563A1 (de) 2001-02-15 2002-02-14 Neues benzoylguanidinsalz

Publications (2)

Publication Number Publication Date
YU61503A true YU61503A (sh) 2006-05-25
RS52014B RS52014B (sr) 2012-04-30

Family

ID=7674094

Country Status (32)

Country Link
US (2) US20080025919A1 (sh)
EP (1) EP1362030B1 (sh)
JP (3) JP4408626B2 (sh)
KR (1) KR100862176B1 (sh)
CN (1) CN1222510C (sh)
AT (1) ATE553078T1 (sh)
AU (1) AU2002250939B2 (sh)
BG (1) BG66330B1 (sh)
BR (1) BR0207867A (sh)
CA (1) CA2434829C (sh)
CY (1) CY1112878T1 (sh)
CZ (1) CZ303277B6 (sh)
DE (1) DE10106970A1 (sh)
DK (1) DK1362030T3 (sh)
EA (1) EA006245B1 (sh)
EC (1) ECSP034708A (sh)
EE (1) EE200300393A (sh)
ES (1) ES2385472T3 (sh)
HK (1) HK1064093A1 (sh)
HR (1) HRP20030653B1 (sh)
HU (1) HU230035B1 (sh)
IL (1) IL156934A (sh)
NO (1) NO20033299L (sh)
NZ (1) NZ528081A (sh)
PL (1) PL213300B1 (sh)
PT (1) PT1362030E (sh)
RS (1) RS52014B (sh)
SI (1) SI1362030T1 (sh)
SK (1) SK287830B6 (sh)
UA (1) UA74625C2 (sh)
WO (1) WO2002064563A1 (sh)
ZA (1) ZA200305365B (sh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
DE10144030A1 (de) * 2001-09-07 2003-03-27 Boehringer Ingelheim Pharma Verbesserung der lokalen Verträglichkeit bei intravenöser Verabreichung von 4-(4-(2-Pyrrolylcarbonyl-1-piperazinyl)-3-trifluormethyl-benzoylguanidin
US6982256B2 (en) 2001-09-07 2006-01-03 Boehringer Ingelheim Pharma Kg Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
US20110118262A1 (en) * 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
US10405746B2 (en) * 2014-04-14 2019-09-10 The University Of Memphis Research Foundation Wireless analog passive sensors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
US6323207B1 (en) * 1998-09-22 2001-11-27 Boehringer Ingelheim Pharma Kg Benzoylguanidine derivatives
DE19843489B4 (de) * 1998-09-22 2006-12-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung
DE10106970A1 (de) * 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Neues Benzoylguanidinsalz
US6730678B2 (en) * 2001-02-15 2004-05-04 Boehringer Ingelheim Pharma Kg Benzoylguanidine salt and hydrates thereof

Also Published As

Publication number Publication date
KR100862176B1 (ko) 2008-10-09
PL362129A1 (en) 2004-10-18
RS52014B (sr) 2012-04-30
PT1362030E (pt) 2012-07-04
NO20033299D0 (no) 2003-07-22
WO2002064563A1 (de) 2002-08-22
CZ20032210A3 (cs) 2003-12-17
EA200300771A1 (ru) 2004-02-26
HK1064093A1 (en) 2005-01-21
JP4408626B2 (ja) 2010-02-03
JP2013107906A (ja) 2013-06-06
NO20033299L (no) 2003-07-22
JP2009235097A (ja) 2009-10-15
SK10202003A3 (sk) 2004-02-03
DK1362030T3 (da) 2012-07-09
ZA200305365B (en) 2004-04-22
CY1112878T1 (el) 2016-04-13
IL156934A0 (en) 2004-02-08
IL156934A (en) 2005-12-18
BG108065A (bg) 2005-01-31
EE200300393A (et) 2003-12-15
CZ303277B6 (cs) 2012-07-11
PL213300B1 (pl) 2013-02-28
HRP20030653B1 (en) 2012-06-30
DE10106970A1 (de) 2002-08-29
CA2434829C (en) 2009-12-08
CN1222510C (zh) 2005-10-12
ECSP034708A (es) 2003-12-24
CN1491213A (zh) 2004-04-21
SK287830B6 (sk) 2011-11-04
ATE553078T1 (de) 2012-04-15
US20080025919A1 (en) 2008-01-31
SI1362030T1 (sl) 2012-07-31
HRP20030653A2 (en) 2005-06-30
HUP0303027A3 (en) 2010-04-28
EP1362030B1 (de) 2012-04-11
EA006245B1 (ru) 2005-10-27
KR20030075197A (ko) 2003-09-22
US20080241077A1 (en) 2008-10-02
BG66330B1 (bg) 2013-06-28
UA74625C2 (en) 2006-01-16
BR0207867A (pt) 2004-03-23
ES2385472T3 (es) 2012-07-25
JP2004518721A (ja) 2004-06-24
AU2002250939B2 (en) 2007-09-06
HUP0303027A2 (hu) 2003-12-29
EP1362030A1 (de) 2003-11-19
NZ528081A (en) 2005-10-28
HU230035B1 (hu) 2015-05-28
CA2434829A1 (en) 2002-08-22
JP5745215B2 (ja) 2015-07-08

Similar Documents

Publication Publication Date Title
EA200700387A1 (ru) Гидраты и полиморфы 4-[[(7r)-8-циклопентил-7-этил-5,6,7,8-тетрагидро-5-метил-6-оксо-2-птеридинил]амино]-3-метокси-n-(1-метил-4-пиперидинил)бензамида, способы их получения и их применение в качестве лекарственных средств
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
HUP0201646A3 (en) Novel alpha-amino acid derivatives, process for producing them and pharmaceutical compositions containing them
WO2003104473A8 (de) Galactosyl-isomalt, verfahren zu seiner herstellung und verwendung
IL191926A0 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
CA2296604A1 (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
MXPA04001968A (es) Agentes antidiabeticos.
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
WO2004035800A3 (en) Intermediate cefdinir salts
HUP0303144A3 (en) Process for the production of substituted 2-(2-pyridylmethyl)sulfinyl-1h-benzimidazoles
CY1112878T1 (el) Νεο αλας βενζοϋλογονανιδινης
IL158998A0 (en) Process for the production of 4-amino-2, 5-bisheterocyclylquinazolines
WO2005037780A3 (de) Amidomethyl-substituierte 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2h-chromen-6-yl-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
NO20043988L (no) Fremgangsmate for fremstilling av chirale 1,4-substituerte piperaziner
AU2002310949A1 (en) Method of producing N-substituted 2,6-dialkyl morpholines
MXPA03008119A (es) Metodo para la produccion de 2,6-dialquilmorfolinas n-sustituidas.
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
MXPA04003477A (es) Sintesis de 4-(piperidil)-(2-piridil)metanona-(e)-o-metiloxima y sales.
MXPA03006534A (es) Metodo para obtener (3-ciano-1h-indol-7-il)-(4(4- fluorfenetil)-piperazin-1-il)-metanona y sus sales.
DK1387837T3 (da) Hidtil ukendte azol- eller triazolderivater, fremgangsmåden til deres fremstilling og deres anvendelse som antimykotiske lægemidler
AU2003222399A1 (en) Process for the synthesis of base addition salts of 2,3-0-isopropylidene-1-0-substituted-5,6-dideoxy-5-n- (4-(2-hydroxy-2-oxoethyl)-phenylaminocarbonyl) amino-l-gulofuranosides
EP1553073A4 (en) PROCESS FOR PREPARING 1,2,4-BUTANTRIOL
WO2004026930A3 (en) The method for reducing inflammation using sti-571 or its salt